U.S., Oct. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07874555) titled 'A Real World Evidence Retrospective Data Collection Study of Edoxaban and Rivaroxaban' on Oct. 08.
Brief Summary: This study aims to evaluate the recommended once-daily dosing of edoxaban and rivaroxaban in patients with atrial fibrillation (AF) and renal dysfunction in South Korea and Taiwan. The findings will contribute to the growing body of evidence needed to guide clinical practice in managing AF patients with renal impairment in Asian populations.
Study Start Date: Dec. 25, 2025
Study Type: OBSERVATIONAL
Condition:
Atrial Fibrillation
Renal Dysfunction
Intervention:
DRUG: Edoxaban
Administered as per label
DRUG: Rivaro...